Nature Communications (Sep 2022)

Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours

  • Yuji Sano,
  • Yumiko Azuma,
  • Toshiaki Tsunenari,
  • Yoko Kayukawa,
  • Junko Shinozuka,
  • Etsuko Fujii,
  • Jun Amano,
  • Yukari Nishito,
  • Toru Maruyama,
  • Yasuko Kinoshita,
  • Yuichiro Sakamoto,
  • Ayae Yoshida,
  • Yoko Miyazaki,
  • Yuta Sato,
  • Chifumi Teramoto-Seida,
  • Takahiro Ishiguro,
  • Takayoshi Tanaka,
  • Takehisa Kitazawa,
  • Mika Endo

DOI
https://doi.org/10.1038/s41467-022-32952-3
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 17

Abstract

Read online

T-cell redirecting bispecific antibodies have emerged as therapeutic agents to promote T-cell mediated killing of tumor cells. Here the authors show that a combination of chemotherapy and ERY974, a bispecific antibody that targets glypican-3 and CD3, facilitates T cell infiltration and promotes anti-tumor responses also in non-inflamed tumors.